144 related articles for article (PubMed ID: 24822208)
41. The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.
Nakamura T; Tanaka N; Higuma N; Kazama T; Kobayashi I; Yokota S
J Am Soc Nephrol; 1996 Nov; 7(11):2434-44. PubMed ID: 8959637
[TBL] [Abstract][Full Text] [Related]
42. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
[TBL] [Abstract][Full Text] [Related]
43. Association of E-selectin gene polymorphism and serum PAPP-A with carotid atherosclerosis in end-stage renal disease.
Issac MS; Afif A; Gohar NA; Fayek NA; Zayed B; Sedrak H; Salah El Din LA
Mol Diagn Ther; 2014 Apr; 18(2):243-52. PubMed ID: 24151105
[TBL] [Abstract][Full Text] [Related]
44. Genetic determination of TNF and myeloperoxidase production in dialyzed patients with diabetic nephropathy.
Buraczynska K; Koziol-Montewka M; Majdan M; Tokarz A; Ksiazek A
Ren Fail; 2004 Nov; 26(6):633-9. PubMed ID: 15600254
[TBL] [Abstract][Full Text] [Related]
45. Single-nucleotide polymorphism of the urokinase-plasminogen activator gene during aging and transformation of human diploid kidney cell cultures.
Beqaj SH; Post D; Ryan JM
In Vitro Cell Dev Biol Anim; 2003; 39(8-9):343-7. PubMed ID: 14686874
[TBL] [Abstract][Full Text] [Related]
46. Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer.
Manchanda PK; Bid HK; Mittal RD
Urol Int; 2006; 77(1):81-4. PubMed ID: 16825821
[TBL] [Abstract][Full Text] [Related]
47. Impact of nitric oxide synthase Glu298Asp polymorphism on the development of end-stage renal disease in type 2 diabetic Egyptian patients.
El-Din Bessa SS; Hamdy SM
Ren Fail; 2011; 33(9):878-84. PubMed ID: 21854353
[TBL] [Abstract][Full Text] [Related]
48. Association of STAT4 polymorphisms with susceptibility to primary membranous glomerulonephritis and renal failure.
Chen SY; Chen CH; Huang YC; Chan CJ; Hsieh YY; Yu MC; Tsai CH; Tsai FJ
Clin Chim Acta; 2011 Oct; 412(21-22):1899-904. PubMed ID: 21740896
[TBL] [Abstract][Full Text] [Related]
49. Association of calcium urolithiasis with urokinase P141L and 3'-UTR C>T polymorphisms in a Japanese population.
Hagikura S; Wakai K; Kawai S; Goto Y; Naito M; Hagikura M; Gotoh M; Hamajima N
Urolithiasis; 2013 Feb; 41(1):47-52. PubMed ID: 23532423
[TBL] [Abstract][Full Text] [Related]
50. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
51. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy.
Tomas NM; Hoxha E; Reinicke AT; Fester L; Helmchen U; Gerth J; Bachmann F; Budde K; Koch-Nolte F; Zahner G; Rune G; Lambeau G; Meyer-Schwesinger C; Stahl RA
J Clin Invest; 2016 Jul; 126(7):2519-32. PubMed ID: 27214550
[TBL] [Abstract][Full Text] [Related]
52. THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1.
Lin F; Zhang D; Chang J; Tang X; Guan W; Jiang G; Zhu C; Bian F
Eur J Med Genet; 2018 Feb; 61(2):84-88. PubMed ID: 29079545
[TBL] [Abstract][Full Text] [Related]
53. Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
Lee JH; Oh MH; Park JS; Na GJ; Gil HW; Yang JO; Lee EY; Hong SY
Korean J Intern Med; 2014 Mar; 29(2):176-82. PubMed ID: 24648800
[TBL] [Abstract][Full Text] [Related]
54. Membranous nephropathy complicated by renal cell carcinoma.
Fujita Y; Kashiwagi T; Takei H; Takada D; Kitamura H; Iino Y; Katayama Y
Clin Exp Nephrol; 2004 Mar; 8(1):59-62. PubMed ID: 15067518
[TBL] [Abstract][Full Text] [Related]
55. Association between scleroderma, renal cell carcinoma and membranous nephropathy.
Nunez S; Konstantinov KN; Servilla KS; Hartshorne MF; Williams WL; Gibel LJ; Tzamaloukas AH
Clin Nephrol; 2009 Jan; 71(1):63-8. PubMed ID: 19203552
[TBL] [Abstract][Full Text] [Related]
56. Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer.
Weng CJ; Lin CW; Chung TT; Tsai CM; Chen MK; Yang SF
Ann Surg Oncol; 2011 Mar; 18(3):805-12. PubMed ID: 21125336
[TBL] [Abstract][Full Text] [Related]
57. Antigen-Specific IgG Subclasses in Primary and Malignancy-Associated Membranous Nephropathy.
von Haxthausen F; Reinhard L; Pinnschmidt HO; Rink M; Soave A; Hoxha E; Stahl RAK
Front Immunol; 2018; 9():3035. PubMed ID: 30619370
[TBL] [Abstract][Full Text] [Related]
58. Nephrotic syndrome as a result of membranous nephropathy caused by renal cell carcinoma.
Kuroda I; Ueno M; Okada H; Shimada S; Akita M; Tsukamoto T; Deguchi N
Int J Urol; 2004 Apr; 11(4):235-8. PubMed ID: 15028103
[TBL] [Abstract][Full Text] [Related]
59. Prognostic factors in idiopathic membranous nephropathy.
Reichert LJ; Koene RA; Wetzels JF
Am J Kidney Dis; 1998 Jan; 31(1):1-11. PubMed ID: 9428445
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy.
Iwakura T; Ohashi N; Kato A; Baba S; Yasuda H
PLoS One; 2015; 10(9):e0138841. PubMed ID: 26393352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
